25.87 USD
+0.09 (+0.35%)
25.84 USD
-0.03 (-0.12%)
We assign a fundamental rating of 3 out of 10 to ELVN. ELVN was compared to 190 industry peers in the Pharmaceuticals industry. While ELVN has a great health rating, there are worries on its profitability. ELVN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year ELVN has reported negative net income.
- ELVN had a negative operating cash flow in the past year.
- ELVN had negative earnings in 4 of the past 5 years.
- ELVN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -19.80%, ELVN perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
- ELVN has a Return On Equity of -20.42%. This is in the better half of the industry: ELVN outperforms 67.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.8% | ||
| ROE | -20.42% | ||
| ROIC | N/A |
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ELVN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ELVN has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, ELVN has more shares outstanding
- There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- ELVN has an Altman-Z score of 61.93. This indicates that ELVN is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 61.93, ELVN belongs to the top of the industry, outperforming 96.84% of the companies in the same industry.
- ELVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 61.93 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ELVN has a Current Ratio of 32.95. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.
- ELVN has a better Current ratio (32.95) than 96.32% of its industry peers.
- ELVN has a Quick Ratio of 32.95. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.
- ELVN has a Quick ratio of 32.95. This is amongst the best in the industry. ELVN outperforms 96.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 32.95 | ||
| Quick Ratio | 32.95 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 3.16% over the past year.
EPS 1Y (TTM)3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 4.29% on average over the next years.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.86%
EPS Next 2Y-2.95%
EPS Next 3Y-12.9%
EPS Next 5Y4.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ELVN. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELVN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ELVN's earnings are expected to decrease with -12.90% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.95%
EPS Next 3Y-12.9%
5. Dividend
5.1 Amount
- ELVN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What is the fundamental rating for ELVN stock?
ChartMill assigns a fundamental rating of 3 / 10 to ELVN.
What is the valuation status of ENLIVEN THERAPEUTICS INC (ELVN) stock?
ChartMill assigns a valuation rating of 0 / 10 to ENLIVEN THERAPEUTICS INC (ELVN). This can be considered as Overvalued.
How profitable is ENLIVEN THERAPEUTICS INC (ELVN) stock?
ENLIVEN THERAPEUTICS INC (ELVN) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for ELVN stock?
The Earnings per Share (EPS) of ENLIVEN THERAPEUTICS INC (ELVN) is expected to grow by 6.86% in the next year.